Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for XNCR

Stock Name	Xencor Inc
Ticker	XNCR(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US98401F1057

Show aggregate XNCR holdings

News associated with XNCR

Barclays Initiates Coverage on Xencor (NASDAQ:XNCR): Research analysts at Barclays began coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a report released on Wednesday, MarketBeat.com reports. The firm set an “underweight” rating and a $6.00 price target on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential downside of 40.18% from the stock’s previous close. A number […] - 2025-09-19 02:46:44
Xencor (NASDAQ:XNCR) Shares Gap Down After Analyst Downgrade: Xencor, Inc. (NASDAQ:XNCR – Get Free Report)’s share price gapped down prior to trading on Wednesday after Bank of America downgraded the stock from a buy rating to a neutral rating. The stock had previously closed at $8.55, but opened at $8.00. Bank of America now has a $12.00 price target on the stock, down […] - 2025-09-05 02:15:52
Xencor (NASDAQ:XNCR) vs. Enliven Therapeutics (NASDAQ:ELVN) Critical Comparison: Xencor (NASDAQ:XNCR – Get Free Report) and Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk. Earnings & Valuation This table compares Xencor and […] - 2025-08-27 04:54:48
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages: Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month target […] - 2025-08-22 02:42:55
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Alps Advisors Inc.: Alps Advisors Inc. lowered its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 9.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,459 shares of the biopharmaceutical company’s stock after selling 5,126 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:25:57
Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by New York State Teachers Retirement System: New York State Teachers Retirement System boosted its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,326 shares of the biopharmaceutical company’s stock after acquiring an additional 1,200 shares during […] - 2025-07-11 05:14:58
Xencor (NASDAQ:XNCR) Trading Down 5.7% Following Insider Selling: Xencor, Inc. (NASDAQ:XNCR – Get Free Report) shares fell 5.7% during trading on Tuesday following insider selling activity. The stock traded as low as $8.67 and last traded at $8.53. 67,899 shares were traded during mid-day trading, a decline of 90% from the average session volume of 664,926 shares. The stock had previously closed at […] - 2025-06-19 02:13:09
Xencor, Inc. (NASDAQ:XNCR) Receives $29.50 Average Target Price from Analysts: Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy […] - 2025-06-11 04:40:45
California State Teachers Retirement System Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR): California State Teachers Retirement System increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 12.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,130 shares of the biopharmaceutical company’s stock after buying an additional 6,376 shares during the period. […] - 2025-06-10 04:22:46
53,397 Shares in Xencor, Inc. (NASDAQ:XNCR) Bought by Public Employees Retirement System of Ohio: Public Employees Retirement System of Ohio acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 53,397 shares of the biopharmaceutical company’s stock, valued at approximately $1,227,000. Other large investors have also modified their holdings of the company. Sterling Capital Management LLC boosted […] - 2025-06-03 05:30:52
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Stock Position in Xencor, Inc. (NASDAQ:XNCR): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 23.4% in the 4th quarter, HoldingsChannel reports. The fund owned 40,355 shares of the biopharmaceutical company’s stock after purchasing an additional 7,650 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Xencor were […] - 2025-05-27 04:46:48
Head to Head Analysis: Xencor (NASDAQ:XNCR) versus Dermata Therapeutics (NASDAQ:DRMA): Xencor (NASDAQ:XNCR – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations. Valuation and Earnings This table compares Xencor and […] - 2025-05-21 03:14:50
Wedbush Weighs in on Xencor’s Q2 Earnings (NASDAQ:XNCR): Xencor, Inc. (NASDAQ:XNCR – Free Report) – Investment analysts at Wedbush cut their Q2 2025 earnings estimates for Xencor in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). […] - 2025-05-13 02:04:46
Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by Tower Research Capital LLC TRC: Tower Research Capital LLC TRC boosted its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 132.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,865 shares of the biopharmaceutical company’s stock after purchasing an additional 4,482 shares during the quarter. Tower Research […] - 2025-05-06 05:17:02
Dimensional Fund Advisors LP Grows Position in Xencor, Inc. (NASDAQ:XNCR): Dimensional Fund Advisors LP grew its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,501,532 shares of the biopharmaceutical company’s stock after purchasing an additional 102,297 shares during the period. Dimensional Fund […] - 2025-05-05 05:21:10
10,408 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Bank of Montreal Can: Bank of Montreal Can purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 10,408 shares of the biopharmaceutical company’s stock, valued at approximately $239,000. Several other institutional investors have also added to or reduced their stakes in XNCR. Finepoint Capital LP […] - 2025-04-25 04:36:48
William Blair Begins Coverage on Xencor (NASDAQ:XNCR): Research analysts at William Blair initiated coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a research note issued on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. Wells Fargo & Company dropped their […] - 2025-04-23 02:11:01
Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by Legal & General Group Plc: Legal & General Group Plc lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 191,514 shares of the biopharmaceutical company’s stock after acquiring an additional 20,141 shares during the quarter. […] - 2025-04-22 04:47:07
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Russell Investments Group Ltd.: Russell Investments Group Ltd. lessened its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 216,291 shares of the biopharmaceutical company’s stock after selling 16,734 shares during the quarter. Russell Investments […] - 2025-04-15 05:33:08
Pictet Asset Management Holding SA Invests $247,000 in Xencor, Inc. (NASDAQ:XNCR): Pictet Asset Management Holding SA acquired a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 10,740 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes […] - 2025-04-11 05:58:59
Norges Bank Makes New Investment in Xencor, Inc. (NASDAQ:XNCR): Norges Bank acquired a new stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 147,823 shares of the biopharmaceutical company’s stock, valued at approximately $3,397,000. A number of other institutional investors and hedge funds have also recently […] - 2025-04-11 05:12:49
Xencor, Inc. (NASDAQ:XNCR) Stock Position Lifted by Vanguard Group Inc.: Vanguard Group Inc. lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,017,366 shares of the biopharmaceutical company’s stock after acquiring an additional 418,040 shares during the period. Vanguard Group Inc. owned 0.11% of Xencor worth $184,239,000 as of its […] - 2025-04-07 05:06:58
Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by Prudential Financial Inc.: Prudential Financial Inc. increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,715 shares of the biopharmaceutical company’s stock after acquiring an additional 6,810 shares during […] - 2025-04-06 05:30:53
Teacher Retirement System of Texas Buys 3,250 Shares of Xencor, Inc. (NASDAQ:XNCR): Teacher Retirement System of Texas boosted its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,645 shares of the biopharmaceutical company’s stock after purchasing an additional 3,250 shares during […] - 2025-04-01 04:40:45
Thrivent Financial for Lutherans Has $2.82 Million Stock Position in Xencor, Inc. (NASDAQ:XNCR): Thrivent Financial for Lutherans grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 122,897 shares of the biopharmaceutical company’s stock after buying an additional 6,528 shares during the quarter. Thrivent Financial […] - 2025-03-28 06:18:47
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts: Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […] - 2025-03-25 04:26:50
Analysts Forecast 25% Upside For VB: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-03-21 08:40:03
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by US Bancorp DE: US Bancorp DE cut its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 75.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,532 shares of the biopharmaceutical company’s stock after selling 7,843 shares during the period. US Bancorp DE’s holdings in Xencor were […] - 2025-03-19 05:10:48
Wells Fargo & Company Cuts Xencor (NASDAQ:XNCR) Price Target to $33.00: Xencor (NASDAQ:XNCR – Free Report) had its target price lowered by Wells Fargo & Company from $37.00 to $33.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. […] - 2025-03-03 04:21:01
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Buy” from Brokerages: Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […] - 2025-02-28 06:35:19

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) XNCR holdings

Date	Number of XNCR Shares Held	Base Market Value of XNCR Shares	Local Market Value of XNCR Shares	Change in XNCR Shares Held	Change in XNCR Base Value	Current Price per XNCR Share Held	Previous Price per XNCR Share Held
2025-12-17 (Wednesday)	51,738	USD 817,460	USD 817,460	-595	USD -48,651	USD 15.8	USD 16.55
2025-12-16 (Tuesday)	52,333	USD 866,111	USD 866,111	-119	USD -14,558	USD 16.55	USD 16.79
2025-12-15 (Monday)	52,452	USD 880,669	USD 880,669	238	USD 18,094	USD 16.79	USD 16.52
2025-12-12 (Friday)	52,214	USD 862,575	USD 862,575	0	USD -28,196	USD 16.52	USD 17.06
2025-12-11 (Thursday)	52,214	USD 890,771	USD 890,771	242	USD -1,069	USD 17.06	USD 17.16
2025-12-10 (Wednesday)	51,972	USD 891,840	USD 891,840	0	USD 18,191	USD 17.16	USD 16.81
2025-12-09 (Tuesday)	51,972	USD 873,649	USD 873,649	0	USD -45,216	USD 16.81	USD 17.68
2025-12-08 (Monday)	51,972	USD 918,865	USD 918,865	0	USD 19,749	USD 17.68	USD 17.3
2025-12-05 (Friday)	51,972	USD 899,116	USD 899,116	0	USD -43,656	USD 17.3	USD 18.14
2025-12-04 (Thursday)	51,972	USD 942,772	USD 942,772	2,360	USD 83,988	USD 18.14	USD 17.31
2025-12-03 (Wednesday)	49,612	USD 858,784	USD 858,784	0	USD 65,488	USD 17.31	USD 15.99
2025-12-02 (Tuesday)	49,612	USD 793,296	USD 793,296	1,785	USD 3,672	USD 15.99	USD 16.51
2025-12-01 (Monday)	47,827	USD 789,624	USD 789,624	0	USD -38,740	USD 16.51	USD 17.32

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of XNCR by Blackrock for IE00BYXG2H39

Show aggregate share trades of XNCR

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-17 SELL -595 15.800* 13.90 Profit of 8,270 on sale
2025-12-16 SELL -119 16.550* 13.89 Profit of 1,653 on sale
2025-12-15 BUY 238 16.790* 13.87
2025-12-11 BUY 242 17.060* 13.85
2025-12-04 BUY 2,360 18.140* 13.77
2025-12-02 BUY 1,785 15.990* 13.74
2025-11-28 BUY 119 17.320* 13.71
2025-11-26 BUY 357 17.380* 13.67
2025-11-25 BUY 595 17.260* 13.66
2025-11-24 BUY 119 16.740* 13.64
2025-11-20 SELL -472 15.575* 13.62 Profit of 6,429 on sale
2025-11-19 BUY 118 15.770* 13.61
2025-11-18 BUY 708 16.020* 13.60
2025-11-17 BUY 236 15.620* 13.59
2025-11-14 BUY 118 14.930* 13.58
2025-11-12 BUY 118 14.390* 13.58
2025-11-10 BUY 118 13.740* 13.57
2025-11-06 BUY 118 14.000* 13.56
2025-11-04 BUY 118 13.700* 13.56
2025-10-30 BUY 590 14.880 14.060 14.142 USD 8,344 13.55
2025-10-29 BUY 238 14.670 15.500 15.417 USD 3,669 13.54
2025-10-22 SELL -472 13.290 14.590 14.460 USD -6,825 13.54 Loss of -432 on sale
2025-10-20 BUY 236 15.070 15.685 15.624 USD 3,687 13.53
2025-10-17 BUY 589 14.770 15.070 15.040 USD 8,859 13.52
2025-10-15 BUY 936 14.100 14.250 14.235 USD 13,324 13.52
2025-10-03 BUY 833 11.770 12.115 12.080 USD 10,063 13.54
2025-10-02 BUY 119 11.820 12.020 12.000 USD 1,428 13.55
2025-09-30 BUY 238 11.730 11.875 11.860 USD 2,823 13.57
2025-09-26 BUY 238 11.570 11.715 11.701 USD 2,785 13.59
2025-09-25 BUY 238 10.330 10.480 10.465 USD 2,491 13.61
2025-09-24 SELL -3,481 10.470 10.660 10.641 USD -37,041 13.63 Profit of 10,395 on sale
2025-09-18 BUY 131 10.030 10.170 10.156 USD 1,330 13.65
2025-09-17 BUY 393 9.250 9.505 9.480 USD 3,725 13.67
2025-08-20 SELL -520 7.510 7.734 7.712 USD -4,010 13.81 Profit of 3,173 on sale
2025-07-30 BUY 512 8.730 9.210 9.162 USD 4,691 14.03
2025-07-17 SELL -258 9.070 9.190 9.178 USD -2,368 14.32 Profit of 1,328 on sale
2025-07-11 SELL -1,032 8.830 9.195 9.158 USD -9,452 14.48 Profit of 5,487 on sale
2025-07-07 BUY 387 7.940 8.440 8.390 USD 3,247 14.64
2025-07-02 BUY 7,150 8.300 8.570 8.543 USD 61,082 14.73
2025-06-20 BUY 3,185 8.540 8.730 8.711 USD 27,745 14.77
2025-06-11 BUY 238 9.520 9.980 9.934 USD 2,364 15.08
2025-06-10 BUY 238 9.740 10.200 10.154 USD 2,417 15.12
2025-06-04 SELL -119 9.100 9.600 9.550 USD -1,136 15.30 Profit of 684 on sale
2025-04-23 BUY 118 10.870 12.430 12.274 USD 1,448 17.26
2025-04-10 SELL -944 7.920 8.620 8.550 USD -8,071 18.04 Profit of 8,963 on sale
2025-04-08 SELL -118 7.670 8.580 8.489 USD -1,002 18.27 Profit of 1,154 on sale
2025-04-07 SELL -118 8.370 8.975 8.915 USD -1,052 18.39 Profit of 1,118 on sale
2025-04-04 SELL -595 8.690 8.870 8.852 USD -5,267 18.50 Profit of 5,740 on sale
2025-04-01 BUY 484 9.690 10.590 10.500 USD 5,082 18.71
2025-03-31 SELL -357 10.640 11.215 11.158 USD -3,983 18.81 Profit of 2,731 on sale
2025-03-21 BUY 1,891 13.200 13.470 13.443 USD 25,421 19.35
2025-03-14 SELL -1,808 12.760 13.120 13.084 USD -23,656 19.80 Profit of 12,136 on sale
2025-03-07 SELL -224 13.870 14.020 14.005 USD -3,137 20.28 Profit of 1,406 on sale
2025-03-04 SELL -112 14.150 14.415 14.388 USD -1,612 20.58 Profit of 694 on sale
2025-02-25 BUY 224 14.450 15.230 15.152 USD 3,394 21.09
2025-02-19 SELL -112 16.200 16.685 16.636 USD -1,863 21.49 Profit of 543 on sale
2025-02-13 BUY 333 16.290 16.700 16.659 USD 5,547 21.90
2025-02-12 BUY 111 16.220 16.250 16.247 USD 1,803 22.02
2025-02-11 BUY 444 16.130 16.645 16.594 USD 7,368 22.14
2025-01-02 BUY 1,009 23.790 24.000 23.979 USD 24,195 23.55
2024-12-30 SELL -541 23.710 24.075 24.039 USD -13,005 23.55 Loss of -266 on sale
2024-11-18 SELL -1,605 23.190 23.440 23.415 USD -37,581 21.77 Loss of -2,634 on sale
2024-11-08 SELL -107 23.620 23.880 23.854 USD -2,552 21.50 Loss of -251 on sale
2024-10-21 SELL -108 21.080 21.590 21.539 USD -2,326 0.00 Loss of -2,326 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-17	SELL	-595			15.800*		13.90 Profit of 8,270 on sale
2025-12-16	SELL	-119			16.550*		13.89 Profit of 1,653 on sale
2025-12-15	BUY	238			16.790*		13.87
2025-12-11	BUY	242			17.060*		13.85
2025-12-04	BUY	2,360			18.140*		13.77
2025-12-02	BUY	1,785			15.990*		13.74
2025-11-28	BUY	119			17.320*		13.71
2025-11-26	BUY	357			17.380*		13.67
2025-11-25	BUY	595			17.260*		13.66
2025-11-24	BUY	119			16.740*		13.64
2025-11-20	SELL	-472			15.575*		13.62 Profit of 6,429 on sale
2025-11-19	BUY	118			15.770*		13.61
2025-11-18	BUY	708			16.020*		13.60
2025-11-17	BUY	236			15.620*		13.59
2025-11-14	BUY	118			14.930*		13.58
2025-11-12	BUY	118			14.390*		13.58
2025-11-10	BUY	118			13.740*		13.57
2025-11-06	BUY	118			14.000*		13.56
2025-11-04	BUY	118			13.700*		13.56
2025-10-30	BUY	590	14.880	14.060	14.142	USD 8,344	13.55
2025-10-29	BUY	238	14.670	15.500	15.417	USD 3,669	13.54
2025-10-22	SELL	-472	13.290	14.590	14.460	USD -6,825	13.54 Loss of -432 on sale
2025-10-20	BUY	236	15.070	15.685	15.624	USD 3,687	13.53
2025-10-17	BUY	589	14.770	15.070	15.040	USD 8,859	13.52
2025-10-15	BUY	936	14.100	14.250	14.235	USD 13,324	13.52
2025-10-03	BUY	833	11.770	12.115	12.080	USD 10,063	13.54
2025-10-02	BUY	119	11.820	12.020	12.000	USD 1,428	13.55
2025-09-30	BUY	238	11.730	11.875	11.860	USD 2,823	13.57
2025-09-26	BUY	238	11.570	11.715	11.701	USD 2,785	13.59
2025-09-25	BUY	238	10.330	10.480	10.465	USD 2,491	13.61
2025-09-24	SELL	-3,481	10.470	10.660	10.641	USD -37,041	13.63 Profit of 10,395 on sale
2025-09-18	BUY	131	10.030	10.170	10.156	USD 1,330	13.65
2025-09-17	BUY	393	9.250	9.505	9.480	USD 3,725	13.67
2025-08-20	SELL	-520	7.510	7.734	7.712	USD -4,010	13.81 Profit of 3,173 on sale
2025-07-30	BUY	512	8.730	9.210	9.162	USD 4,691	14.03
2025-07-17	SELL	-258	9.070	9.190	9.178	USD -2,368	14.32 Profit of 1,328 on sale
2025-07-11	SELL	-1,032	8.830	9.195	9.158	USD -9,452	14.48 Profit of 5,487 on sale
2025-07-07	BUY	387	7.940	8.440	8.390	USD 3,247	14.64
2025-07-02	BUY	7,150	8.300	8.570	8.543	USD 61,082	14.73
2025-06-20	BUY	3,185	8.540	8.730	8.711	USD 27,745	14.77
2025-06-11	BUY	238	9.520	9.980	9.934	USD 2,364	15.08
2025-06-10	BUY	238	9.740	10.200	10.154	USD 2,417	15.12
2025-06-04	SELL	-119	9.100	9.600	9.550	USD -1,136	15.30 Profit of 684 on sale
2025-04-23	BUY	118	10.870	12.430	12.274	USD 1,448	17.26
2025-04-10	SELL	-944	7.920	8.620	8.550	USD -8,071	18.04 Profit of 8,963 on sale
2025-04-08	SELL	-118	7.670	8.580	8.489	USD -1,002	18.27 Profit of 1,154 on sale
2025-04-07	SELL	-118	8.370	8.975	8.915	USD -1,052	18.39 Profit of 1,118 on sale
2025-04-04	SELL	-595	8.690	8.870	8.852	USD -5,267	18.50 Profit of 5,740 on sale
2025-04-01	BUY	484	9.690	10.590	10.500	USD 5,082	18.71
2025-03-31	SELL	-357	10.640	11.215	11.158	USD -3,983	18.81 Profit of 2,731 on sale
2025-03-21	BUY	1,891	13.200	13.470	13.443	USD 25,421	19.35
2025-03-14	SELL	-1,808	12.760	13.120	13.084	USD -23,656	19.80 Profit of 12,136 on sale
2025-03-07	SELL	-224	13.870	14.020	14.005	USD -3,137	20.28 Profit of 1,406 on sale
2025-03-04	SELL	-112	14.150	14.415	14.388	USD -1,612	20.58 Profit of 694 on sale
2025-02-25	BUY	224	14.450	15.230	15.152	USD 3,394	21.09
2025-02-19	SELL	-112	16.200	16.685	16.636	USD -1,863	21.49 Profit of 543 on sale
2025-02-13	BUY	333	16.290	16.700	16.659	USD 5,547	21.90
2025-02-12	BUY	111	16.220	16.250	16.247	USD 1,803	22.02
2025-02-11	BUY	444	16.130	16.645	16.594	USD 7,368	22.14
2025-01-02	BUY	1,009	23.790	24.000	23.979	USD 24,195	23.55
2024-12-30	SELL	-541	23.710	24.075	24.039	USD -13,005	23.55 Loss of -266 on sale
2024-11-18	SELL	-1,605	23.190	23.440	23.415	USD -37,581	21.77 Loss of -2,634 on sale
2024-11-08	SELL	-107	23.620	23.880	23.854	USD -2,552	21.50 Loss of -251 on sale
2024-10-21	SELL	-108	21.080	21.590	21.539	USD -2,326	0.00 Loss of -2,326 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of XNCR

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	441,043	0	699,169	63.1%
2025-09-18	355,320	0	679,372	52.3%
2025-09-17	293,259	0	484,819	60.5%
2025-09-16	102,817	0	219,248	46.9%
2025-09-15	305,857	0	441,747	69.2%
2025-09-12	139,184	0	241,197	57.7%
2025-09-11	116,085	0	466,595	24.9%
2025-09-10	131,941	0	251,550	52.5%
2025-09-09	65,693	0	308,391	21.3%
2025-09-08	129,677	0	214,365	60.5%
2025-09-05	110,573	0	181,052	61.1%
2025-09-04	69,315	0	426,047	16.3%
2025-09-03	131,061	0	222,780	58.8%
2025-09-02	113,883	0	274,944	41.4%
2025-08-29	109,964	0	426,341	25.8%
2025-08-28	90,002	0	140,217	64.2%
2025-08-27	296,442	0	650,723	45.6%
2025-08-26	144,450	0	345,869	41.8%
2025-08-25	119,736	93	238,937	50.1%
2025-08-22	195,210	0	362,906	53.8%
2025-08-21	51,998	100	96,810	53.7%
2025-08-20	35,468	51	62,333	56.9%
2025-08-19	69,073	0	115,302	59.9%
2025-08-18	78,716	0	116,552	67.5%
2025-08-15	56,553	0	121,857	46.4%
2025-08-14	83,825	0	189,102	44.3%
2025-08-13	94,738	0	327,899	28.9%
2025-08-12	139,640	0	379,024	36.8%
2025-08-11	145,558	0	325,986	44.7%
2025-08-08	139,427	0	278,210	50.1%
2025-08-07	167,696	25	428,188	39.2%
2025-08-06	117,300	61	197,833	59.3%
2025-08-05	86,400	0	230,657	37.5%
2025-08-04	79,179	0	198,927	39.8%
2025-08-01	100,453	0	414,166	24.3%
2025-07-31	94,623	83	234,870	40.3%
2025-07-30	168,910	0	227,320	74.3%
2025-07-29	71,672	0	104,991	68.3%
2025-07-28	89,957	0	120,690	74.5%
2025-07-25	78,077	0	136,932	57.0%
2025-07-24	116,760	0	178,384	65.5%
2025-07-23	179,865	0	277,405	64.8%
2025-07-22	106,613	3,584	223,164	47.8%
2025-07-21	72,476	0	170,108	42.6%
2025-07-18	72,227	0	112,643	64.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE